OSAKA, Japan, February 9, 2026

日本大阪，2026年2月9日

- Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.) announces today that its group company, Torii Pharmaceutical Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President and Chief Executive Officer: Nobumasa Kondo), has issued a press release announcing the launch in Japan of YCANTH.

盐野义制药株式会社（总部：日本大阪；首席执行官：手代木功博士）今日宣布，其集团公司鸟居药品株式会社（总部：日本东京都中央区；总裁兼首席执行官：近藤伸昌）已发布新闻稿，宣布在日本推出YCANTH。

®

®

topical solution 0.71% for the Treatment of Molluscum Contagiosum.

用于治疗传染性软疣的0.71%局部溶液。

Below is the announcement released by Torii Pharmaceutical.

以下是鸟居制药发布的公告。

Torii Pharmaceutical Co., Ltd. (Torii) is pleased to announce today the launch of YCANTH

鸟居制药株式会社（Torii）今天欣然宣布推出YCANTH。

®

®

topical solution 0.71% (cantharidin) for the treatment of molluscum contagiosum in Japan. This product received manufacturing and marketing approval in Japan for the indication of molluscum contagiosum, a common pediatric skin infection, on September 19, 2025, and has been listed on the Japanese National Health Insurance (NHI) drug price list on November 12, 2025..

0.71%的外用溶液（斑蝥素）在日本被用于治疗传染性软疣。该产品于2025年9月19日获得日本制造和销售许可，适应症为传染性软疣，这是一种常见的儿童皮肤感染，并已于2025年11月12日被列入日本国家健康保险（NHI）药品价格目录。

YCANTH

YCANTH

®

®

topical solution 0.71% is a topical solution for the treatment of molluscum contagiosum in patients (≥2 years old) that use cantharidin as its active ingredient. While the exact mechanism of action of YCANTH

0.71%的外用溶液是一种用于治疗传染性软疣患者的外用溶液（≥2岁），其活性成分为斑蝥素。尽管YCANTH的确切作用机制尚不明确。

®

®

is not fully understood, it is thought that when applied to the affected area, it activates neutral serine proteases, weakening epidermal desmosomes of the epidermis and breaks down the epidermal structure, and leading to the formation of intraepidermal blisters at the application site. The formation of these blisters causes the affected skin to peel off.

尚未完全理解，但认为当应用于受影响区域时，它会激活中性丝氨酸蛋白酶，削弱表皮的桥粒，破坏表皮结构，从而导致在应用部位形成表皮内水疱。这些水疱的形成使受损皮肤剥落。

The resulting peeling of the skin is believed to remove the virus-infected tissue, thereby providing a therapeutic effect..

由此产生的皮肤脱皮被认为可以去除受病毒感染的组织，从而提供治疗效果。

In the Phase 3 clinical program of YCANTH

在YCANTH的III期临床项目中

®

®

topical solution 0.71% in patients with molluscum contagiosum (≥2 years old) in Japan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety of YCANTH

在日本，0.71%的局部溶液用于治疗传染性软疣（≥2岁）患者时，其主要疗效终点已显示出优于对照组。此外，YCANTH的安全性

®

®

topical solution 0.71% was confirmed and there were no observed issues of tolerability for the application.

0.71%的局部溶液得到确认，且应用过程中未观察到耐受性问题。

Torii expects YCANTH

Torii 期望 YCANTH

®

®

topical solution 0.71% to be a new option for the treatment of molluscum contagiosum patients (≥2 years old) in Japan.

0.71%的外用溶液将成为日本治疗传染性软疣患者（≥2岁）的新选择。

In the United States, Verrica Pharmaceuticals Inc. (Verrica) received approval for YCANTH

在美国，Verrica Pharmaceuticals Inc.（Verrica）获得了YCANTH的批准。

®

®

from the U.S. Food and Drug Administration in July 2023 for the topical treatment of molluscum contagiosum in adult and pediatric patients (≥2 years old) and launched YCANTH

2023年7月，美国食品和药物管理局批准用于成人和儿科患者（≥2岁）传染性软疣的局部治疗，并推出了YCANTH。

®

®

in the US in August 2023.

2023年8月在美国。

＜YCANTH

＜YCANTH

®

®

topical solution 0.71% Information＞

局部溶液 0.71% 信息＞

Product name                                  YCANTH

产品名称                                  YCANTH

®

®

topical solution 0.71%

局部溶液 0.71%

Generic Name                                  Cantharidin

通用名称：斑蝥素

Indications                                       Molluscum Contagiosum

适应症：传染性软疣

Dosage and administration              For adults and pediatric patients (≥2 years old), apply an appropriate amount of solution to the affected area once every 3 weeks during treatment. 16 to 24 hours after application, washing affected area with soap.

剂量与用法：成人及儿科患者（≥2岁），治疗期间每3周在患处涂抹适量溶液一次。涂抹后16至24小时，用肥皂清洗患处。

Package                                           Glass Ampoule Applicator：0.45mL×5 （One braking tool attached）

包装：玻璃安瓿瓶涂抹器：0.45毫升×5（附带一个折断工具）

NHI Drug Price                                 ¥14,995.60（0.71% 0.45mL）

国家健康保险药物价格 ¥14,995.60（0.71% 0.45毫升）

Approval Date                                  September 19, 2025

批准日期                                  2025年9月19日

NHI Pricing Date                              November 12, 2025

NHI定价日期                              2025年11月12日

Launch Date                                     February 9, 2026

发射日期：2026年2月9日

Distributor                                        Torii Pharmaceutical Co., Ltd.

经销商                                                鸟居制药株式会社

Import source                                   Verrica Pharmaceuticals Inc.

进口来源                                   Verrica Pharmaceuticals Inc.

ABOUT Molluscum Contagiosum

关于传染性软疣

Molluscum contagiosum is a highly contagious viral skin infection caused by the molluscum contagiosum virus, a member of the poxviridae family, commonly known as 'water warts.' It primarily affects children and is characterized by small, shiny papules (1–4 mm in diameter) on the trunk and extremities..

传染性软疣是一种高度传染性的病毒性皮肤感染，由痘病毒科的传染性软疣病毒引起，俗称“水瘊子”。它主要影响儿童，特征是躯干和四肢上出现小而有光泽的丘疹（直径1-4毫米）。

ABOUT Common Warts

关于寻常疣

Common warts (Verruca vulgaris) are a common dermatologic disease caused by infection with the human papillomavirus (HPV), commonly known as “warts”. They typically appear keratinized, raised bumps (several mm to 1 cm) on the hands and feet.

常见疣（Verruca vulgaris）是一种由人乳头瘤病毒（HPV）感染引起的常见皮肤病，通常称为“疣”。它们通常表现为手部和脚部上角化、隆起的肿块（数毫米至1厘米）。

For Further Information, Contact:

如需更多信息，请联系：

SHIONOGI Website Inquiry Form :

SHIONOGI网站咨询表：

https://www.shionogi.com/global/en/contact.html

https://www.shionogi.com/global/en/contact.html